Shenzhen Evergreen Therapeutics Co. Ltd.

Analysis

Shenzhen Evergreen Therapeutics Co. Ltd. is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across distinct examiners and 2 distinct art units, indicating that the company's patenting efforts cover multiple technical sub-sectors within the biotech field. This distribution requires a strategy that can accommodate the different examination standards of separate units. The applicant must be prepared for varying levels of scrutiny across these different technical domains.

The busiest examiner for the portfolio is DAHLIN, HEATHER RAQUEL, who is responsible for 1 pending office action. Since each of the distinct examiners is handling a pending action, the company's prosecution workload is split. This prevents any single examiner from having an outsized impact on the entire portfolio, but it also means the applicant must navigate the individual styles of distinct examiners simultaneously. This requires a flexible and well-coordinated legal strategy to ensure consistency across the company's intellectual property.

With pending office actions in total, the company faces a moderate level of prosecution activity. The presence of 2 distinct art units suggests that the legal team must be prepared for different prior art landscapes and technical requirements in each case. By addressing the 1 pending office action under DAHLIN, HEATHER RAQUEL and the other action separately, the company can advance its intellectual property interests across different areas of Biotechnology & Pharmaceuticals. This multi-front approach is common for companies with diverse therapeutic pipelines.